Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis

Abstract

RANKL is highly expressed in active LCH at the lesional level, concomitant to p65 NFκB activation. The use of RANKL inhibition as a rational therapeutic approach of the disease now needs further clinical evaluation.